The federal government approach of discouraging and even penalizing provincial innovations that fall outside federal preferences has helped ensure the overpriced and under-performing status quo.
The government will likely need to borrow to finance any new spending and add more debt, which will result in higher taxes in the future. And yet, pharmacare is being presented to Canadians as if there’s no direct cost to them.